Formula Pharmaceuticals, Inc. is a privately-held, oncology drug development company advancing novel medicines to address areas of unmet therapeutic need in cancer. Formula's lead program involves a Chimeric Antigen Receptor (CAR) technology using Cytokine Induced Killer (CIK) cells and proprietary non-viral plasmid-based transfection methods.